The Drug Regulatory Authority of Pakistan has promised that Sinovac’s influenza vaccine will reach the market by November 15, following reports of a shortage that has left Islamabad’s residents searching desperately for protection against seasonal flu. Meanwhile, other established brands are reportedly unlikely to reach consumers this season. Nearly six years after the pandemic laid bare the weaknesses of Pakistan’s healthcare system, the capital is confronting another entirely foreseeable shortage. One wonders how many warnings it takes before preparedness becomes more than a talking point.
The country has been here before. In November 2020, medical professionals raised the alarm over the unavailability of influenza vaccines. Six months later, COVID vaccination centres in Karachi were turning people away amid supply disruptions. The National Command and Operation Centre subsequently demonstrated that coordinated procurement, digital records and targeted vaccination drives could still deliver results. Yet, by December 2023, another influenza vaccine shortage had surfaced, forcing DRAP to arrange 80,000 additional doses. The warning signs have continued to pile up. In August 2025, the Pakistan Medical Association warned that at least 80 important medicines were unavailable, including 25 without substitutes. Only last month, the National Assembly heard about a shortage affecting an imported insulin product. International supply disruptions have certainly played their part, but patients cannot be expected to bear the consequences of inadequate contingency planning indefinitely.Buy Maps
The latest episode has also raised questions about regulatory oversight. Virionza, an available influenza vaccine, reportedly carries a maximum retail price of Rs1,304, while its regulatory barcode displays Rs654. Such discrepancies do little to inspire confidence in a system ostensibly designed to protect consumers.
Meanwhile, influenza will hardly wait for official assurances. At Karachi’s Jinnah Postgraduate Medical Centre, daily presentations with flu-like symptoms rose from 30-40 to 70-80 in late October. The World Health Organisation estimates that seasonal influenza causes three to five million severe illnesses and between 290,000 and 650,000 respiratory deaths worldwide annually. Pregnant women, older adults, young children and people with chronic illnesses face particularly serious risks.
While DRAP and the health ministry deserve recognition for pursuing alternative supplies amid international disruptions, the larger question remains unanswered. Why should routine preventive healthcare remain so vulnerable to shortages and administrative delays?
Advance procurement, dependable stock reporting, transparent pricing and affordable vaccination for vulnerable groups should be standard practice. So should disease surveillance capable of spotting the warning signs long before hospital waiting rooms begin filling up.
